Raymond James & Associates’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $9.38M | Sell |
86,931
-21,174
| -20% | -$2.31M | 0.01% | 1270 |
|
|
2024
Q2 | $11.7M | Buy |
108,105
+5,039
| +5% | +$594K | 0.01% | 1078 |
|
|
2024
Q1 | $13.6M | Sell |
103,066
-22,827
| -18% | -$2.85M | 0.01% | 993 |
|
|
2023
Q4 | $15.3M | Sell |
125,893
-93,401
| -43% | -$10.4M | 0.01% | 858 |
|
|
2023
Q3 | $24.6M | Sell |
219,294
-29,872
| -12% | -$3.79M | 0.02% | 600 |
|
|
2023
Q2 | $36.3M | Sell |
249,166
-4,514
| -2% | -$613K | 0.03% | 462 |
|
|
2023
Q1 | $32.8M | Buy |
253,680
+77,992
| +44% | +$9.79M | 0.03% | 487 |
|
|
2022
Q4 | $22.4M | Buy |
175,688
+14,351
| +9% | +$1.67M | 0.02% | 618 |
|
|
2022
Q3 | $16.9M | Sell |
161,337
-46,102
| -22% | -$5.06M | 0.02% | 690 |
|
|
2022
Q2 | $21.8M | Sell |
207,439
-164,332
| -44% | -$19.5M | 0.02% | 587 |
|
|
2022
Q1 | $47.5M | Buy |
371,771
+37,815
| +11% | +$4.56M | 0.04% | 376 |
|
|
2021
Q4 | $41.2M | Buy |
333,956
+30,748
| +10% | +$4.02M | 0.03% | 443 |
|
|
2021
Q3 | $43.1M | Buy |
303,208
+26,210
| +9% | +$3.86M | 0.04% | 403 |
|
|
2021
Q2 | $43.3M | Buy |
276,998
+45,424
| +20% | +$7.36M | 0.04% | 397 |
|
|
2021
Q1 | $36M | Buy |
231,574
+45,481
| +24% | +$7.05M | 0.04% | 416 |
|
|
2020
Q4 | $27.8M | Sell |
186,093
-66,828
| -26% | -$9.44M | 0.03% | 477 |
|
|
2020
Q3 | $33.4M | Sell |
252,921
-12,073
| -5% | -$1.58M | 0.04% | 362 |
|
|
2020
Q2 | $30.7M | Buy |
264,994
+712
| +0.3% | +$82K | 0.04% | 373 |
|
|
2020
Q1 | $25.9M | Buy |
264,282
+6,573
| +3% | +$862K | 0.04% | 362 |
|
|
2019
Q4 | $37.5M | Buy |
257,709
+85,588
| +50% | +$11.8M | 0.05% | 351 |
|
|
2019
Q3 | $22.9M | Buy |
172,121
+27,283
| +19% | +$3.52M | 0.03% | 496 |
|
|
2019
Q2 | $16.6M | Buy |
144,838
+27,061
| +23% | +$3.17M | 0.02% | 615 |
|
|
2019
Q1 | $14.6M | Buy |
117,777
+5,701
| +5% | +$648K | 0.02% | 640 |
|
|
2018
Q4 | $11.3M | Buy |
112,076
+9,525
| +9% | +$1.07M | 0.02% | 697 |
|
|
2018
Q3 | $13.1M | Buy |
102,551
+2,671
| +3% | +$318K | 0.02% | 707 |
|
|
2018
Q2 | $10.8M | Buy |
99,880
+1,332
| +1% | +$145K | 0.02% | 772 |
|
|
2018
Q1 | $10.4M | Buy |
98,548
+205
| +0.2% | +$23.8K | 0.02% | 756 |
|
|
2017
Q4 | $11.5M | Sell |
98,343
-15,611
| -14% | -$1.77M | 0.02% | 692 |
|
|
2017
Q3 | $13M | Sell |
113,954
-14,762
| -11% | -$1.7M | 0.03% | 612 |
|
|
2017
Q2 | $16M | Buy |
128,716
+2,666
| +2% | +$316K | 0.03% | 515 |
|
|
2017
Q1 | $14.9M | Sell |
126,050
-10,746
| -8% | -$1.22M | 0.03% | 511 |
|
|
2016
Q4 | $13.7M | Sell |
136,796
-40,612
| -23% | -$4.35M | 0.04% | 496 |
|
|
2016
Q3 | $22.4M | Sell |
177,408
-14,246
| -7% | -$1.76M | 0.06% | 314 |
|
|
2016
Q2 | $22.4M | Buy |
191,654
+2,929
| +2% | +$331K | 0.07% | 285 |
|
|
2016
Q1 | $19.5M | Buy |
188,725
+27,233
| +17% | +$2.63M | 0.07% | 314 |
|
|
2015
Q4 | $16.1M | Buy |
161,492
+22,049
| +16% | +$2.16M | 0.06% | 356 |
|
|
2015
Q3 | $12.7M | Buy |
139,443
+16,540
| +13% | +$1.66M | 0.05% | 401 |
|
|
2015
Q2 | $13M | Buy |
122,903
+51,986
| +73% | +$5.75M | 0.05% | 427 |
|
|
2015
Q1 | $8.09M | Buy |
70,917
+18,362
| +35% | +$2.1M | 0.04% | 534 |
|
|
2014
Q4 | $5.79M | Buy |
52,555
+6,755
| +15% | +$712K | 0.03% | 613 |
|
|
2014
Q3 | $4.47M | Buy |
45,800
+21,993
| +92% | +$2.16M | 0.03% | 683 |
|
|
2014
Q2 | $2.4M | Buy |
23,807
+765
| +3% | +$74.6K | 0.01% | 992 |
|
|
2014
Q1 | $2.12M | Buy |
23,042
+9,541
| +71% | +$879K | 0.01% | 1005 |
|
|
2013
Q4 | $1.22M | Buy |
+13,501
| New | +$1.17M | 0.01% | 1206 |
|
Other funds holding ZBH
Raymond James & Associates's ZBH Position: Q3 2024 in Review
Raymond James & Associates reduced its Zimmer Biomet (ZBH) stake by 20% in Q3 2024, selling an estimated $2.31M and leaving 86,931 shares worth $9.38M. The position accounts for 0.01% of the portfolio, ranked #1270.
Raymond James & Associates first reported a position in ZBH in Q4 2013 and has held it in 44 quarters since. The position peaked at $47.5M in Q1 2022. 981 funds tracked by Wall St. Rank hold ZBH as of Q3 2024.
- Raymond James & Associates held 86,931 shares of Zimmer Biomet worth $9.38M as of Q3 2024.
- Raymond James & Associates sold 21,174 Zimmer Biomet shares in Q3 2024, an estimated $2.31M.
- Zimmer Biomet made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1270 holding.
- Raymond James & Associates first reported a position in Zimmer Biomet in Q4 2013 and has held it in 44 quarters since.
- Raymond James & Associates's Zimmer Biomet position peaked at $47.5M in Q1 2022.
- 981 funds tracked by Wall St. Rank held Zimmer Biomet as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.